Opinion|Videos|August 21, 2024
CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Advertisement
Related to this article
After two relapses of acute lymphoblastic leukemia, Hannah Koepsell received CAR-T cell therapy. A pediatric oncologist explains why leukemia can return after treatment and how researchers are working to make CAR-T responses last longer.
Researchers are studying whether combining CAR-T cell therapy with targeted drugs could help children with high-risk leukemia, including infants whose cancer may be more likely to return after treatment.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Welireg Plus Lenvima for Advanced Kidney Cancer After Immunotherapy
2
7 Breast Cancer Clinical Trials Currently Enrolling in the US
3
10 Things That Got Me Through Treatment feat. Sally Kalksma
4
What to Do Before Your Chemo Infusion: A Checklist From People Who've Been There
5